Therapeutic compounds

1. A compound of formula I:

wherein

A is 3-6 membered carbocycle;

n is 0, 1, or 2;

m is 0, 1, or 2;

R 1 is

each Z 1 is independently (C 1 -C 6 )alkyl, (C 3 -C 7 )carbocycle, halogen, or —CN, wherein any (C 1 -C 6 )alkyl or (C 3 -C 7 )carbocycle of Z 1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1a groups, wherein the Z 1a groups are the same or different;

each Z 1a is independently halogen, (C 3 -C 7 )carbocycle, —OH, or —CN;

R 2 is hydrogen, halogen, —OH, or —CN;

R 3 is (C 1 -C 6 )alkyl or 3-5 membered heterocycle, wherein the (C 1 -C 6 )alkyl is unsubstituted or substituted with 1, 2, or 3 halogen atoms;

R 4 is hydrogen, —S(O) 2 -(C 1 -C 6 )alkyk, —S(O) 2 -(C 3 -C 6 )carbocycle, or 5-6 membered heteroaryl, wherein any —S(O) 2 —(C 1 -C 6 ) alkyl, —S(O) 2 —(C 3 -C 6 )carbocycle, or 5-6 membered heteroaryl of R 4 is unsubstituted or substituted with 1, 2, or 3 Z 2 groups, wherein the Z 2 groups are the same or different;

Z 2 is (C 1 -C 6 )alkyl or (C 3 -C 6 )carbocycle, wherein any (C 1 -C 6 )alkyl or (C 3 -C 6 )carbocycle is unsubstituted or substituted with 1, 2, or 3 Z 2 a groups, wherein the Z 2 a groups are the same or different;

Z 2a is hydroxyl or halogen;

R 5 is hydrogen or halogen; and

R 6 is (C 1 -C 3 )alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is a compound of formula Ia:

wherein:

n is 0, 1, or 2;

m is 0 or 1;

each Z 1 is independently (C 1 -C 6 )alkyl, (C 3 -C 7 )carbocycle, or halogen, wherein any (C 1 -C 6 )alkyl or (C 3 -C 7 )carbocycle of Z 1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1a groups, wherein the Z 1a groups are the same or different;

each Z 1a is independently halogen or (C 3 -C 7 )carbocycle;

R 2 is hydrogen or iodide;

R 3 is (C 1 -C 2 )alkyl or 3-5 membered heterocycle, wherein the (C 1 -C 2 )alkyl is unsubstituted or substituted with 2 or 3 halogen atoms;

R 4 is hydrogen, —S(O) 2 —(C 1 -C 2 )alkyl, —S(O) 2 -cyclopropyl, or 5-membered heteroaryl, wherein any —S(O) 2 —(C 1 -C 2 )alkyl, —S(O) 2 -cyclopropyl, or 5-membered heteroaryl of R 4 is unsubstituted or substituted with 1, 2, or 3 Z 2 groups, wherein the Z 2 groups are the same or different;

Z 2 is (C 1 -C 3 )alkyl or cyclopropyl, wherein any (C 1 -C 3 )alkyl or cyclopropyl is unsubstituted or substituted with 1, 2, or 3 Z 2a groups, wherein the Z 2a groups are the same or different;

Z 2a is hydroxyl or fluorine;

R 5 is hydrogen, chorine, or fluorine; and

R 6 is (C 1 -C 3 )alkyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1, or 2;

m is 0 or 1;

each Z 1 is independently (C 1 -C 6 )alkyl, (C 3 -C 7 )carbocycle, or halogen, wherein any (C 1 -C 6 )alkyl or (C 3 -C 7 )carbocycle of Z 1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1a groups, wherein the Z 1a groups are the same or different;

each Z i a is independently halogen or (C 3 -C 7 )carbocycle;

R 2 is hydrogen or iodide;

R 3 is (C 1 -C 2 )alkyl or 3-5 membered heterocycle, wherein the (C 1 -C 2 )alkyl is unsubstituted or substituted with 2 or 3 fluorine atoms;

R 4 is hydrogen, —S(O) 2 —(C 1 -C 2 )alkyl, —S(O) 2 -cyclopropyl, or 5-membered heteroaryl, wherein any —S(O) 2 —(C 1 -C 2 )alkyl, —S(O) 2 -cyclopropyl, or 5-membered heteroaryl of R 4 is unsubstituted or substituted with 1, 2, or 3 Z 2 groups, wherein the Z 2 groups are the same or different;

Z 2 is (C 1 -C 3 )alkyl or cyclopropyl, wherein any (C 1 -C 3 )alkyl or cyclopropyl is unsubstituted or substituted with 1, 2, or 3 Z 2a groups, wherein the Z 2a groups are the same or different;

Z 2a is hydroxyl or fluorine;

R 5 is hydrogen, chorine, or fluorine; and

R 6 is methyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1, or 2;

m is 0 or 1;

each Z 1 is independently (C 1 -C 6 )alkyl, (C 3 -C 7 )carbocycle, or halogen, wherein any (C 1 -C 6 )alkyl or (C 3 -C 7 )carbocycle of Z 1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z 1a groups, wherein the Z 1a groups are the same or different;

each Z 1a is independently halogen or (C 3 -C 7 )carbocycle;

R 2 is hydrogen;

R 3 is (C 1 -C 2 )alkyl or 4-membered heterocycle, wherein the (C 1 -C 2 )alkyl is unsubstituted or substituted with 2 or 3 fluorine atoms;

R 4 is —S(O) 2 —(C 1 -C 2 )alkyl, —S(O) 2 -cyclopropyl, or 5-membered heteroaryl, wherein any —S(O) 2 -(C 1 -C 2 )alkyl, —S(O) 2 -cyclopropyl, or 5-membered heteroaryl of R 4 is unsubstituted or substituted with 1, 2, or 3 Z 2 groups, wherein the Z 2 groups are the same or different;

Z 2 is (C1-C3)alkyl or cyclopropyl, wherein any (C1-C3)alkyl or cyclopropyl is unsubstituted or substituted with 1, 2, or 3 Z 2a groups, wherein the Z 2a groups are the same or different;

Z 2a is hydroxyl or fluorine;

R 5 is hydrogen, chorine, or fluorine; and

R 6 is methyl.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 1.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 0.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z 1 is (C 1 -C 6 )alkyl substituted with 2 or 3 halogen atoms, a cyclopropyl group, or halogen.

14. The compound of any one of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen or iodide.

15. The compound of any one of claims 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is (C 1 -C 3 )alkyl or a 4-membered heterocycle, wherein the (C 1 -C 3 )alkyl is unsubstituted or substituted with 1, 2, or 3 halogen atoms.

16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is methyl, —CH 2 CHF 2 , —CH 2 CF 3 , or

17. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen, —S(O) 2 -(C 1 - 2 )alkyl, —S(O) 2 -cyclopropyl, or an oxadiazole, wherein any —S(O) 2 -(C 1 - 2 )alkyl, —S(O) 2 -cyclopropyl, or oxadiazole of R 4 is unsubstituted or substituted with 1, 2, or 3 Z 2 groups, wherein the Z 2 groups are the same or different.

18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is

19. The compound of any one of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen, chloride, or fluoride.

20. The compound of any one of claim 1 , or a pharmaceutically acceptable salt thereof, which is

21. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

22. A method for treating a HIV infection in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to the patient.

23. A method for treating an HIV infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of an additional therapeutic agent, wherein the additional therapeutic agent is a HIV protease inhibitor, a HIV non-nucleoside or non-nucleotide inhibitor of reverse transcriptase, a HIV nucleoside or nucleotide inhibitor of reverse transcriptase, a HIV integrase inhibitor, a HIV non-catalytic site integrase inhibitor, an HIV entry inhibitor, an HIV maturation inhibitor, a latency reversing agent, a compound that targets the HIV capsid, an immune-based therapy, a phosphatidylinositol 3-kinase (PI3K) inhibitor, a HIV antibody, a bispecific antibody, an antibody-like therapeutic protein, a HIV p17 matrix protein inhibitor, a IL-13 antagonist, a peptidyl-prolyl cis-trans isomerase A modulator, a protein disulfide isomerase inhibitor, a complement C5a receptor antagonist, a DNA methyltransferase inhibitor, a HIV vif gene modulator, a Vif dimerization antagonist, a HIV-1 viral infectivity factor inhibitor, a TAT protein inhibitor, a HIV-1 Nef modulator, a Hck tyrosine kinase modulator, a mixed lineage kinase-3 (MLK-3) inhibitor, a HIV-1 splicing inhibitor, a Rev protein inhibitor, an integrin antagonist, a nucleoprotein inhibitor, a splicing factor modulator, a COMM domain containing protein 1 modulator, a HIV ribonuclease H inhibitor, a retrocyclin modulator, a CDK-9 inhibitor, a dendritic ICAM-3 grabbing nonintegrin 1 inhibitor, a HIV GAG protein inhibitor, a HIV POL protein inhibitor, a Complement Factor H modulator, a ubiquitin ligase inhibitor, a deoxycytidine kinase inhibitor, a cyclin dependent kinase inhibitor, a proprotein convertase PC9 stimulator, a ATP dependent RNA helicase DDX3X inhibitor, a reverse transcriptase priming complex inhibitor, a G6PD and NADH-oxidase inhibitor, a pharmacokinetic enhancer, a HIV gene therapy, or a HIV vaccine.